Therapeutics News and Research

RSS

FDA extends action date for inhaled Treprostinil (Tyvaso) NDA by three months

United Therapeutics Corporation has announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the New Drug Application (NDA) for Tyvaso (inhaled treprostinil).

30 Apr 2009

Oral delivery system for RNAi therapeutics

Researchers at the University of Massachusetts Medical School (UMMS) report on a novel approach to the delivery of small bits of genetic material in order to silence genes using "RNA interference"-and in the process, discovered a potent method of suppressing inflammation in mice similar to what occurs in a range of human diseases.

30 Apr 2009

Research may bring drugs with triple the absorbing power and lower toxic risks

Drug makers might be able to triple the absorbing power of some medications and lower toxic risks of others, as a result of a study at the University of Maryland, Baltimore on how bile acids travel through the gut.

29 Apr 2009

Discovery of two important molecules that underlie the pathology of lupus, particularly kidney disease

Kidney damage associated with the autoimmune disease lupus is linked to a malfunction of immune cells that causes them to congregate in and attack the organs, researchers at UT Southwestern Medical Center have discovered in a mouse study.

22 Apr 2009

Retooled chemotherapy agents for drug delivery may increase effectiveness

Researchers may have found a way to combine imaging with chemotherapy in a single agent for the treatment of prostate cancer, according to data presented at the American Association for Cancer Research 100th Annual Meeting 2009

22 Apr 2009

Novel microparticle-based immune response modifier shows broad effects against recurrent or metastatic cancer

MIS416, a novel microparticle-based immune response modifier, demonstrated the ability to significantly reduce the number and size of metastatic tumors in preclinical mouse models of lung and breast cancers, Innate Therapeutics (formerly Virionyx Corporation) announced.

22 Apr 2009

A link found between health literacy, happiness

A new University of Alabama at Birmingham (UAB) study published in the advanced online edition of the journal Social Indicators Research suggests a link between the ease with which older adults can access and understand health information and their happiness.

21 Apr 2009

Stem cell therapy used to fight amyotrophic lateral sclerosis

A team of Utahns is collaborating on a stem cell therapy to fight amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

21 Apr 2009

Brain manufactures proteins that act like marijuana

U.S. and Brazilian scientists have just proven that one of Bob Dylan's most famous lines - "everybody must get stoned" - is correct.

20 Apr 2009

First compound for receptors in schizophrenia and Alzheimer's holds promise

For almost 20 years, pharmacological companies have known that certain compounds that activate two specific CNS receptors, causing them to release the neurotransmitter acetylcholine, are effective in treating the cognitive and motor problems related to both schizophrenia and Alzheimer's disease (AD).

20 Apr 2009

Lab study shows THC exposure as adolescents linked to negative effects of THC as adults

In earlier studies, researchers at Louisiana State University had found that estrogen - or more precisely, having ovaries - made adult rats exposed for the first time to THC, the primary ingredient in marijuana and hashish, less sensitive to THC's negative effects on tests of learning and memory.

20 Apr 2009

Federal funding for partnership to combat infectious diseases

Oregon Health & Science University and the University of Washington, along with a number of partner institutions across the Northwest, have received federal funding to form a regional research center aimed at combating emerging or re-emerging infectious diseases that pose a serious threat to human health.

15 Apr 2009

Experimental insulin-like growth factor receptor inhibitor a clear clinical candidate for pancreatic cancer therapy

Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

14 Apr 2009